Tag: Neuromuscular Disease
-
Vyvgart Moves Into Autoimmune Muscle Disease After Phase 3 Win
Vyvgart Hytrulo met the primary endpoint in the Phase 3 ALKIVIA study, strengthening argenx’s case for expanding FcRn inhibition into autoimmune muscle disease.
-
Can New Data Rescue Capricor’s Duchenne Cell Therapy at the FDA?
Capricor is submitting new 24-month upper-limb data for deramiocel after an FDA advisory committee voted against the existing efficacy evidence, reopening the regulatory debate around the DMD cell therapy.